Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Resatorvid (TAK-242) is a selective inhibitor of Toll-like receptor 4 (TLR4). Resatorvid binds directly to Cys747 and prevents TLR4 from binding to TIRAP, thereby blocking downstream signaling. Resatorvid has antitumor activity, anti-inflammatory activity, and neuroprotective effects.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 45.00 | |
2 mg | In stock | $ 64.00 | |
5 mg | In stock | $ 97.00 | |
10 mg | In stock | $ 167.00 | |
25 mg | In stock | $ 323.00 | |
50 mg | In stock | $ 528.00 | |
100 mg | In stock | $ 848.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 118.00 |
Description | Resatorvid (TAK-242) is a selective inhibitor of Toll-like receptor 4 (TLR4). Resatorvid binds directly to Cys747 and prevents TLR4 from binding to TIRAP, thereby blocking downstream signaling. Resatorvid has antitumor activity, anti-inflammatory activity, and neuroprotective effects. |
Targets&IC50 | TNF R:1.9 nM , IL-6:1.3 nM , NO:1.8 nM |
In vitro |
METHODS: Breast cancer cell lines MCF7, SKBR3, MDA-MB-231 and BT-474 were treated with Resatorvid (10-150 µM) for 48 h. Cell viability was measured using MTT Assay. RESULTS: Resatorvid dose-dependently inhibited the viability of breast cancer cell lines. [1] METHODS: Macrophage RAW264.7 was treated with Resatorvid (1-100 nM) and LPS (5 ng/mL), IFN-γ (1 U/mL) for 4 h. Gene expression levels were measured by RT-qPCR. RESULTS: Resatorvid inhibited LPS and IFN-γ induced mRNA expression of IL-6 and TNF-α in RAW264.7 cells. [2] |
In vivo |
METHODS: To test the effects on cancer-comorbid depression (BCCD), Resatorvid (3 mg/kg) was administered intraperitoneally to BALB/c mice in the BCCD model once daily for three weeks. RESULTS: Resatorvid attenuated the symptoms of BCCD mice in vivo.Resatorvid inactivated inflammatory factors and TLR4/NF-κB/NLRP3 signaling pathway in vivo. [3] METHODS: To investigate the effects on temporomandibular joint osteoarthritis (TMJOA), Resatorvid (10 mg/kg) was injected intraperitoneally twice weekly for four weeks into a CFA-induced TMJOA model in C57BL/6 mice. RESULTS: Prophylactic treatment with Resatorvid attenuated TMJOA pathology by inhibiting chondrocyte focal prolapse and degeneration, and ROS-induced macrophage inflammation via TLR4/MyD88/NF-κB/NLRP3. [4] |
Cell Research | Cell Line: RAW264.7 cells. Concentration: 1 nM, 10 nM, 100 nM. Incubation Time: 4 hours [1] |
Animal Research | Animal Model: 30 ApoE knockout and 30 wild-type mice on a C57BL/6 background (female, 10 weeks old). Dosage: 0.3?mg/kg. Administration: i.p.; twice a week; for 4 weeks [3] |
Synonyms | CLI-095, TAK-242 |
Molecular Weight | 361.82 |
Formula | C15H17ClFNO4S |
CAS No. | 243984-11-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: Insoluble
DMSO: 100 mg/mL (276.38 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Resatorvid 243984-11-4 Apoptosis Autophagy Immunology/Inflammation TNF TLR Interleukin Inhibitor TAK 242 MyD88 inhibit TNF-R inflammatory diseases CLI-095 TNFR TAK-242 TRIF TNF Receptor CLI 095 CLI095 Tumor Necrosis Factor Receptor TAK242 Toll-like Receptor (TLR) Interleukin Related IL-6 inhibitor